On Thursday, officials from the U.S. Food and Drug Administration (FDA) unveiled a new artificial intelligence (AI) system during the Food and Drug Law Institute’s (FDLI) Annual Meeting. This innovative system aims to streamline and consolidate over 40 different application data sources across all FDA centers.
Left to right: FDA’s Sridhar Mantha, Tiffany Branch, and Steven Musser
The newly introduced system, named HALO (Harmonized AI and Lifecycle Operation), complements version 4.0 of the FDA’s existing Elsa tool. According to the FDA, the integration of HALO and Elsa will allow staff to query data and create workflows more efficiently, eliminating the need for manually uploading documents for each interaction. This consolidation is expected to significantly enhance the agency’s AI capabilities.
Panel Discussion
During the panel discussion, FDA representatives addressed the functionalities of HALO and the application of AI tools in various areas, including the processing of Freedom of Information Act (FOIA) requests.
The session was moderated by Tala Fakhouri, Vice President of Consulting at Parexel and former Associate Director for Data Science and AI Policy at the FDA.
Sridhar Mantha, Acting Chief Information Officer for the Office of Digital Transformation at the FDA, described HALO as a comprehensive data platform designed to integrate more than 40 unique applications, submission data sources, systems, and portals across all FDA centers. “This is a singular data platform that maintains the highest level of security. Data is compartmentalized and segmented by center,” said Mantha, emphasizing that the platform aggregates information from all centers.
“This is quite impressive. Many organizations have not yet reached the level of an integrated data platform,” Fakhouri remarked.
Tiffany Branch, Director of the Office of Management and Enterprise Services within the Office of the Commissioner, highlighted the effectiveness of AI in processing FOIA requests. The FDA has reported an 85% increase in efficiency for handling these requests compared to previous manual methods. “We receive 12,000 FOIA requests annually, with a 20 percent increase each year. This is where AI can be particularly beneficial,” Branch noted.
When Fakhouri inquired whether AI is employed in inspections, Steven Musser, the FDA’s Associate Commissioner for Human Foods, offered a nuanced perspective. He expressed skepticism about AI’s effectiveness in inspections due to the challenges inspectors face in integrating AI-generated information on-site. However, he acknowledged that AI excels in identifying “anomalous patterns in imports and economically motivated adulteration,” and in extracting insights that may elude human observers.
In conclusion, the FDA’s introduction of the HALO system marks a significant step forward in integrating AI into its operations. This initiative not only aims to enhance data management efficiencies but also seeks to ensure a more effective and streamlined approach to overseeing public health matters.
